Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 9/2017

01-09-2017 | Original Article

Antimicrobial effects of Manuka honey on in vitro biofilm formation by Clostridium difficile

Authors: M. Piotrowski, P. Karpiński, H. Pituch, A. van Belkum, P. Obuch-Woszczatyński

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 9/2017

Login to get access

Abstract

Clostridium difficile is the cause of the nosocomial C. difficile infection (CDI). The conventional antibiotics used in CDI therapy are often unsuccessful, and recurrent infections may occur. Biofilm formation by C. difficile is associated with chronic or recurrent infections; biofilms may contribute to virulence and impaired antimicrobial efficacy. Manuka honey, derived from the Manuka tree (Leptospermum scoparium), is known to exhibit antimicrobial properties that are associated with its significant content of methylglyoxal, a natural antibiotic. The aim of the present study was to determine the antimicrobial effect of Manuka honey on clinical C. difficile strains belonging to four prominent polymerase chain reaction (PCR) ribotypes (RTs) (RT017, RT023, RT027 and RT046) and on their biofilm formation in vitro. Minimal inhibitory and bactericidal concentrations (MICs and MBCs, respectively) were determined using the broth dilution method. The biomass of the biofilm and the clearance of C. difficile biofilms by Manuka honey were determined using the crystal violet staining method. The MIC and MBC of Manuka honey for C. difficile strains were equal at 6.25% (v/v). PCR RT027 strains produced more biofilm in vitro than the other examined strains. Manuka honey effectively inhibited biofilm formation by C. difficile strains of different PCR RTs.
Literature
2.
go back to reference McFarland LV, Surawicz CM, Stamm WE (1990) Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis 162:678–684CrossRefPubMed McFarland LV, Surawicz CM, Stamm WE (1990) Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis 162:678–684CrossRefPubMed
3.
go back to reference Davies KA, Ashwin H, Longshaw CM, Burns DA, Davis GL, Wilcox MH; EUCLID study group (2016) Diversity of Clostridium difficile PCR ribotypes in Europe: results from the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID), 2012 and 2013. Euro Surveill 21(29). doi:10.2807/1560-7917.ES.2016.21.29.30294 Davies KA, Ashwin H, Longshaw CM, Burns DA, Davis GL, Wilcox MH; EUCLID study group (2016) Diversity of Clostridium difficile PCR ribotypes in Europe: results from the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID), 2012 and 2013. Euro Surveill 21(29). doi:10.​2807/​1560-7917.​ES.​2016.​21.​29.​30294
4.
go back to reference Pituch H, Obuch-Woszczatyński P, Lachowicz D, Wultańska D, Karpiński P, Młynarczyk G, van Dorp SM, Kuijper EJ; Polish Clostridium difficile Study Group (2015) Hospital-based Clostridium difficile infection surveillance reveals high proportions of PCR ribotypes 027 and 176 in different areas of Poland, 2011 to 2013. Euro Surveill 20(38). doi: 10.2807/1560-7917.ES.2015.20.38.30025 Pituch H, Obuch-Woszczatyński P, Lachowicz D, Wultańska D, Karpiński P, Młynarczyk G, van Dorp SM, Kuijper EJ; Polish Clostridium difficile Study Group (2015) Hospital-based Clostridium difficile infection surveillance reveals high proportions of PCR ribotypes 027 and 176 in different areas of Poland, 2011 to 2013. Euro Surveill 20(38). doi: 10.​2807/​1560-7917.​ES.​2015.​20.​38.​30025
5.
go back to reference Bartlett JG (2006) Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 145:758–764CrossRefPubMed Bartlett JG (2006) Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 145:758–764CrossRefPubMed
6.
go back to reference Vedantam G, Clark A, Chu M, McQuade R, Mallozzi M, Viswanathan VK (2012) Clostridium difficile infection: toxins and non-toxin virulence factors, and their contributions to disease establishment and host response. Gut Microbes 3:121–134. doi:10.4161/gmic.19399 CrossRefPubMedPubMedCentral Vedantam G, Clark A, Chu M, McQuade R, Mallozzi M, Viswanathan VK (2012) Clostridium difficile infection: toxins and non-toxin virulence factors, and their contributions to disease establishment and host response. Gut Microbes 3:121–134. doi:10.​4161/​gmic.​19399 CrossRefPubMedPubMedCentral
7.
go back to reference Tasteyre A, Barc MC, Karjalainen T, Dodson P, Hyde S, Bourlioux P, Borriello P (2000) A Clostridium difficile gene encoding flagellin. Microbiology 146:957–966CrossRefPubMed Tasteyre A, Barc MC, Karjalainen T, Dodson P, Hyde S, Bourlioux P, Borriello P (2000) A Clostridium difficile gene encoding flagellin. Microbiology 146:957–966CrossRefPubMed
8.
go back to reference Chapetón Montes D, Candela T, Collignon A, Janoir C (2011) Localization of the Clostridium difficile cysteine protease Cwp84 and insights into its maturation process. J Bacteriol 193:5314–5321. doi:10.1128/JB.00326-11 CrossRef Chapetón Montes D, Candela T, Collignon A, Janoir C (2011) Localization of the Clostridium difficile cysteine protease Cwp84 and insights into its maturation process. J Bacteriol 193:5314–5321. doi:10.​1128/​JB.​00326-11 CrossRef
9.
10.
go back to reference Malone M, Bjarnsholt T, McBain AJ, James GA, Stoodley P, Leaper D, Tachi M, Schultz G, Swanson T, Wolcott RD (2017) The prevalence of biofilms in chronic wounds: a systematic review and meta-analysis of published data. J Wound Care 26:20–25. doi:10.12968/jowc.2017.26.1.20 CrossRefPubMed Malone M, Bjarnsholt T, McBain AJ, James GA, Stoodley P, Leaper D, Tachi M, Schultz G, Swanson T, Wolcott RD (2017) The prevalence of biofilms in chronic wounds: a systematic review and meta-analysis of published data. J Wound Care 26:20–25. doi:10.​12968/​jowc.​2017.​26.​1.​20 CrossRefPubMed
12.
go back to reference Crowther GS, Chilton CH, Todhunter SL, Nicholson S, Freeman J, Baines SD, Wilcox MH (2014) Comparison of planktonic and biofilm-associated communities of Clostridium difficile and indigenous gut microbiota in a triple-stage chemostat gut model. J Antimicrob Chemother 69:2137–2147. doi:10.1093/jac/dku116 CrossRefPubMed Crowther GS, Chilton CH, Todhunter SL, Nicholson S, Freeman J, Baines SD, Wilcox MH (2014) Comparison of planktonic and biofilm-associated communities of Clostridium difficile and indigenous gut microbiota in a triple-stage chemostat gut model. J Antimicrob Chemother 69:2137–2147. doi:10.​1093/​jac/​dku116 CrossRefPubMed
13.
go back to reference Mah TF, O’Toole GA (2001) Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 9:34–39CrossRefPubMed Mah TF, O’Toole GA (2001) Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 9:34–39CrossRefPubMed
14.
go back to reference Mathur H, Rea MC, Cotter PD, Hill C, Ross RP (2016) The efficacy of thuricin CD, tigecycline, vancomycin, teicoplanin, rifampicin and nitazoxanide, independently and in paired combinations against Clostridium difficile biofilms and planktonic cells. Gut Pathog 8:20. doi:10.1186/s13099-016-0102-8 CrossRefPubMedPubMedCentral Mathur H, Rea MC, Cotter PD, Hill C, Ross RP (2016) The efficacy of thuricin CD, tigecycline, vancomycin, teicoplanin, rifampicin and nitazoxanide, independently and in paired combinations against Clostridium difficile biofilms and planktonic cells. Gut Pathog 8:20. doi:10.​1186/​s13099-016-0102-8 CrossRefPubMedPubMedCentral
16.
go back to reference Stubbs SLJ, Brazier JS, O’Neill GL, Duerden BI (1999) PCR targeted to the 16S–23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 37:461–463PubMedPubMedCentral Stubbs SLJ, Brazier JS, O’Neill GL, Duerden BI (1999) PCR targeted to the 16S–23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 37:461–463PubMedPubMedCentral
17.
go back to reference Stepanovic S, Vukovic D, Dakic I, Savic B, Svabic-Vlahovic M (2000) A modified microtiter-plate test for quantification of staphylococcal biofilm formation. J Microbiol Methods 40:175–179CrossRefPubMed Stepanovic S, Vukovic D, Dakic I, Savic B, Svabic-Vlahovic M (2000) A modified microtiter-plate test for quantification of staphylococcal biofilm formation. J Microbiol Methods 40:175–179CrossRefPubMed
18.
go back to reference Maddocks SE, Lopez MS, Rowlands RS, Cooper RA (2012) Manuka honey inhibits the development of Streptococcus pyogenes biofilms and causes reduced expression of two fibronectin binding proteins. Microbiology 158:781–790. doi:10.1099/mic.0.053959-0 CrossRefPubMed Maddocks SE, Lopez MS, Rowlands RS, Cooper RA (2012) Manuka honey inhibits the development of Streptococcus pyogenes biofilms and causes reduced expression of two fibronectin binding proteins. Microbiology 158:781–790. doi:10.​1099/​mic.​0.​053959-0 CrossRefPubMed
19.
20.
go back to reference Cooper RA, Halas E, Molan PC (2002) The efficacy of honey in inhibiting strains of Pseudomonas aeruginosa from infected burns. J Burn Care Rehabil 23:366–370CrossRefPubMed Cooper RA, Halas E, Molan PC (2002) The efficacy of honey in inhibiting strains of Pseudomonas aeruginosa from infected burns. J Burn Care Rehabil 23:366–370CrossRefPubMed
Metadata
Title
Antimicrobial effects of Manuka honey on in vitro biofilm formation by Clostridium difficile
Authors
M. Piotrowski
P. Karpiński
H. Pituch
A. van Belkum
P. Obuch-Woszczatyński
Publication date
01-09-2017
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 9/2017
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-017-2980-1

Other articles of this Issue 9/2017

European Journal of Clinical Microbiology & Infectious Diseases 9/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine